Provita Poliklinika Sp. z o.o.

Warsaw 14 trials 3 recruiting

14 Registered trials

3 Currently recruiting

Organisation

Provita Poliklinika Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100045569

Address

Baboszewska 1 Lok 2u4, 02-674, Poland

Departments

Clinical Trial
Dermatologia
Gastroenterology
N/A
N/D
NA
NA/ND
Oncology
Private practice

Clinical trials at this site (14)

Search interface

A Randomized, Double-Blind, Placebo Controlled, Multi - Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients… Pending

2024-514520-16-00 mild-to-moderate active ulcerative colitis 3
A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7… Pending

2024-515439-31-00 Alopecia areata 5
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants from Approximately 2 Months of Age Recruiting

2023-507600-32-00 Pneumococcal Immunization 5 2025-05-22
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co… Recruiting

2025-520690-39-00 Moderately to Severely Active Ulcerative Colitis (UC) 4 2025-11-04
Cytisine for nicotine-containing electronic cigarette and tobacco cigarette cessation: a randomized placebo-controlled trial Recruiting

2023-504708-27-00 electronic cigarette cessation 5 2024-11-02
A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended

2024-515438-33-00 Alopecia areata 5 2026-01-12
A study to determine the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa Ended

2024-519736-17-00 Hidradenitis Suppurativa 4 2025-10-03
Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers,… Ended

2023-510465-10-00 Meningococcal immunization 4 2025-03-10
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi… Ended

2023-509089-39-00 Non-Muscle Invasive Bladder Cancer 5 2020-07-01
A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa… Ended

2023-508377-82-00 Hidradenitis Suppurativa (HS) 10 2024-06-27
Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended

2023-508177-85-00 Healthy volunteers (Meningococcal infection) 5 2024-03-12
MENACWY=MEN7B-003 Ended

2023-506449-40-00 Infections, Meningococcal 9 2021-11-29